First Time Loading...

Editas Medicine Inc
NASDAQ:EDIT

Watchlist Manager
Editas Medicine Inc Logo
Editas Medicine Inc
NASDAQ:EDIT
Watchlist
Price: 5.6 USD 2% Market Closed
Updated: Apr 23, 2024

Editas Medicine Inc
Free Cash Flow

Last Value
3-Years CAGR
5-Years CAGR
Quarterly
Annual
TTM
|

Editas Medicine Inc
Free Cash Flow Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Free Cash Flow Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Editas Medicine Inc
NASDAQ:EDIT
Free Cash Flow
$-136.9m
CAGR 3-Years
10%
CAGR 5-Years
-22%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Free Cash Flow
$22.1B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Free Cash Flow
$7.4B
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
10%
Amgen Inc
NASDAQ:AMGN
Free Cash Flow
$7.4B
CAGR 3-Years
-9%
CAGR 5-Years
-7%
CAGR 10-Years
3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Free Cash Flow
$3.3B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Free Cash Flow
$3.7B
CAGR 3-Years
22%
CAGR 5-Years
15%
CAGR 10-Years
24%

See Also

What is Editas Medicine Inc's Free Cash Flow?
Free Cash Flow
-136.9m USD

Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Free Cash Flow amounts to -136.9m USD.

What is Editas Medicine Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-22%

Over the last year, the Free Cash Flow growth was 25%. The average annual Free Cash Flow growth rates for Editas Medicine Inc have been 10% over the past three years , -22% over the past five years .